BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$51.32
Price+0.27%
$0.14
1Y
Price
Market Cap
$9.811b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-8096.8%
EBITDA Margin-3388.2%
Net Profit Margin-
Free Cash Flow MarginRevenue
$235.812m
+2255.4%
1y CAGR+726.3%
3y CAGR+731.0%
5y CAGREarnings
-$776.415m
+29.4%
1y CAGR+7.3%
3y CAGR-2.5%
5y CAGREPS
-$4.09
+33.4%
1y CAGR+13.3%
3y CAGR+8.0%
5y CAGRBook Value
-$1.778b
$1.080b
Assets$2.859b
Liabilities$2.677b
DebtDebt to Assets
247.8%
-4.2x
Debt to EBITDAFree Cash Flow
-$665.871m
+7.0%
1y CAGR+1.6%
3y CAGR-7.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company